NuVasive Company Profile (NASDAQ:NUVA)

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

NuVasive, Inc. (NASDAQ:NUVA) issued its quarterly earnings data on Tuesday, April, 25th. The company reported $0.38 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.37 by $0.01. The company had revenue of $249.86 million for the quarter, compared to analyst estimates of $250.52 million. NuVasive had a net margin of 5.35% and a return on equity of 12.63%. The company's revenue was up 16.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.34 earnings per share. View NuVasive's Earnings History.

NuVasive updated its FY17 earnings guidance on Tuesday, April, 25th. The company provided EPS guidance of $2.00 for the period, compared to the Thomson Reuters consensus estimate of $2.02. The company issued revenue guidance of $1.065 billion, compared to the consensus revenue estimate of $1.07 billion.

10 brokers have issued 12-month price objectives for NuVasive's stock. Their forecasts range from $70.00 to $90.00. On average, they anticipate NuVasive's stock price to reach $82.11 in the next twelve months. View Analyst Ratings for NuVasive.

Here are some recent quotes from research analysts about NuVasive stock:

• 1. According to Zacks Investment Research, "For the last three months, NuVasive has been trading above the Zacks categorized Medical Product industry. Over the recent past, the company has demonstrated steady year-over-year improvement on the top-line front on account of strong procedural growth in the U.S. as well as internationally. NuVasive’s strong momentum in the U.S. and international businesses in the last-reported first quarter also raises optimism. We are also optimistic about the company’s recent progress in development of technologies and services for spine surgery. On the flip side, the stock’s valuation is quite stretched. Further, currency headwind, pricing and reimbursement issues and competitive landscape are major downsides. Also, per management, the company’s low-margin Biotronic business impacted the last reported first quarter’s performance." (7/4/2017)
• 2. Canaccord Genuity analysts commented, "We note leading indicators of forward growth — new product flow (Less-ray, cervical iGA, Unite, pediatric deformity, expandable cages) and sales rep additions (+15 percent Y/Y in 2016) — should drive incremental growth opportunities entering the H2/16," the analyst said.On Track to Deliver Meaningful LeverageCanaccord Genuity believes the company is on track to deliver meaningful leverage over the next five years, although it expects M&A and continued investments to offset near-term improvements in operating margins."In sum, we continue to view the margin story positively but expect 2017 to be back-end loaded as NUVA realizes the benefits of sales force investments (building out peds team) and marketing efforts in Japan," the firm said.Guidance Reflects Changing SeasonalityThe firm noted that the company guided full-year revenues to $1.065 million, including a $10 million forex headwind, adjusted operating margins of 17.1 percent, up 100 basis points year-over-year, and earnings of $2 per share. However, the second quarter revenue guidance of $262 million was about $5 million below the consensus estimate, the firm added.According to the firm, this reflects the changing seasonality of the revenue cadence post the Ellipse Biotronic acquisitions. Concluding, the firm said, "We continue to believe that NuVasive is in prime share-taking position in the global spine market, driven by innovative new product flow, robust sales force additions, and broader tailwinds such as vendor consolidation."Furthermore, the margin expansion story remains intact and we see upside bias to estimates despite the second-half weighted guidance." (4/26/2017)
• 3. UBS AG analysts commented, "The company's long-term operating margin goal of 25% was a key topic of discussion last week when we hosted NUVA for investor meetings. Management laid out a clear pathway to 25% operating margins (from 16.1% currently), which included: 1) 400 bps from in-source manufacturing; 2) 400 bps from asset efficiencies; 3) 400 bps from OUS scalability; and 4) 200 bps from sales force efficiencies, offset by 500 bps of R&D investment and pricing headwinds. We reiterate our Buy rating on NUVA and $82 price target and expect consistent execution and margin improvements to drive the stock higher." (3/20/2017)

Some companies that are related to NuVasive include STERIS PLC (STE), Bio-Rad Laboratories (BIO), West Pharmaceutical Services (WST), DexCom (DXCM), Hill-Rom Holdings (HRC), VWR Corporation (VWR), Integra LifeSciences Holdings Corporation (IART), ICU Medical (ICUI), LivaNova PLC (LIVN), Neogen Corporation (NEOG), Nevro Corp. (NVRO), Haemonetics Corporation (HAE), Inogen (INGN), Halyard Health (HYH), MiMedx Group (MDXG), CONMED Corporation (CNMD), Asante Solutions (PUMP) and K2M Group Holdings (KTWO).

NuVasive's management team includes the folowing people:

• Gregory T. Lucier, Chairman of the Board, Chief Executive Officer
• Jason M. Hannon, President, Chief Operating Officer
• Matthew W. Link, President - U.S. Commercial
• Patrick S. Miles, Vice Chairman of the Board
• Quentin S. Blackford, Chief Financial Officer, Executive Vice President Head of Strategy and Corporate Integrity
• Edmund J. Roschak, Chief Executive Officer of NuVasive Specialized Orthopedics, Inc.
• Joan B. Stafslien, Executive Vice President, General Counsel, Corporate Secretary
• Carol A. Cox, Executive Vice President - External Affairs and Corporate Marketing
• Peter Michael Leddy Ph.D., Executive Vice President, Global Human Resources, Integrations, Real Estate and Internal Communications
• Vickie L. Capps, Independent Director

NuVasive's stock is owned by many different of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (2.61%), NN Investment Partners Holdings N.V. (0.08%), Profit Investment Management LLC (0.07%), Insight Capital Research & Management Inc. (0.05%), State Treasurer State of Michigan (0.04%) and Sanders Morris Harris LLC (0.04%). Company insiders that own NuVasive stock include Jason Hannon, Joan Stafslien, Lesley H Howe, Matthew Link, Michael D Ohalleran, Patrick Miles, Quentin S Blackford and Russell Powers. View Institutional Ownership Trends for NuVasive.

NuVasive's stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Insight Capital Research & Management Inc., Profit Investment Management LLC, Capstone Asset Management Co., US Bancorp DE, Sheets Smith Wealth Management and Malaga Cove Capital LLC. Company insiders that have sold NuVasive stock in the last year include Jason Hannon, Lesley H Howe and Matthew Link. View Insider Buying and Selling for NuVasive.

NuVasive's stock was bought by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, NN Investment Partners Holdings N.V., Legato Capital Management LLC, Bank of Montreal Can, Oregon Public Employees Retirement Fund, Aperio Group LLC, LS Investment Advisors LLC and Louisiana State Employees Retirement System. Company insiders that have bought NuVasive stock in the last two years include Joan Stafslien, Michael D Ohalleran and Patrick Miles. View Insider Buying and Selling for NuVasive.

Shares of NuVasive can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NuVasive stock can currently be purchased for approximately $79.92.